Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025)
Sutro Biopharma recorded quarterly Return on Capital Employed of 135.81% in Q4 2025, down 20.1% quarter-over-quarter from 113.08% in Q3 2025, and down 5290.0% year-over-year from 2.62% in Q4 2024.
Sutro Biopharma's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 135.81% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 5290.0% year-over-year to 135.81%; the TTM figure through Dec 2025 stood at 135.81% (down 5290.0% YoY), while the FY2025 annual figure was 77.11%, up 316.0% from the prior year.
- Return on Capital Employed came in at 135.81% for Q4 2025 at Sutro Biopharma, down from 113.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.3% in Q2 2021 to a low of 135.81% in Q4 2025.
- A 5-year average of 52.75% and a median of 39.61% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 2900 bps in 2021 and sank 8417 bps in 2025, its largest moves.
- Sutro Biopharma's Return on Capital Employed stood at 31.31% in 2021, then fell by 22 bps to 38.23% in 2022, then surged by 35 bps to 24.97% in 2023, then plunged by 232 bps to 82.9% in 2024, then sank by 64 bps to 135.81% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 135.81%, 113.08%, and 94.21% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - | -135.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.81% |
| Sep 30, 2025 | -113.08% |
| Jun 30, 2025 | -94.21% |
| Mar 31, 2025 | -113.15% |
| Dec 31, 2024 | -82.90% |
| Sep 30, 2024 | -38.34% |
| Jun 30, 2024 | -33.56% |
| Mar 31, 2024 | -28.98% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | -48.48% |
| Jun 30, 2023 | -46.13% |
| Mar 31, 2023 | -40.88% |
| Dec 31, 2022 | -38.23% |
| Sep 30, 2022 | -34.27% |
| Jun 30, 2022 | -42.73% |
| Mar 31, 2022 | -41.81% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | -26.75% |
| Jun 30, 2021 | -19.30% |
| Mar 31, 2021 | -20.04% |
| Dec 31, 2020 | -22.13% |
| Sep 30, 2020 | -23.24% |
| Jun 30, 2020 | -35.02% |
| Mar 31, 2020 | -49.05% |
| Dec 31, 2019 | -42.32% |
| Sep 30, 2019 | -30.45% |
| Jun 30, 2019 | -25.94% |
| Mar 31, 2019 | -21.90% |
| Dec 31, 2018 | -25.21% |